Semaglutide and cardiovascular risk - Revision history

Prab: /* SEO: semaglutide cardiovascular risk near me */

2026-07-13T03:39:44Z

SEO: semaglutide cardiovascular risk near me

← Older revision		Revision as of 03:39, 13 July 2026
Line 537:		Line 537:
	</div>		</div>

	==~~SEO: semaglutide~~ cardiovascular risk near me==		==Semaglutide cardiovascular risk reduction near me==

	Patients searching for '''semaglutide cardiovascular risk near me''', '''Wegovy heart risk reduction NYC''', '''Wegovy cardiovascular doctor Brooklyn''', '''semaglutide heart attack risk Philadelphia''', '''Ozempic cardiovascular risk New Jersey''', '''GLP-1 heart benefits Pennsylvania''', '''weight loss heart disease doctor NYC''', or '''Wegovy prior authorization cardiovascular disease''' often want a medical practice that can combine obesity medicine, cardiovascular-risk awareness, sleep apnea screening, and medication access support.		Patients searching for '''semaglutide cardiovascular risk near me''', '''Wegovy heart risk reduction NYC''', '''Wegovy cardiovascular doctor Brooklyn''', '''semaglutide heart attack risk Philadelphia''', '''Ozempic cardiovascular risk New Jersey''', '''GLP-1 heart benefits Pennsylvania''', '''weight loss heart disease doctor NYC''', or '''Wegovy prior authorization cardiovascular disease''' often want a medical practice that can combine obesity medicine, cardiovascular-risk awareness, sleep apnea screening, and medication access support.

Prab at 03:37, 13 July 2026

2026-07-13T03:37:15Z

← Older revision		Revision as of 03:37, 13 July 2026
Line 69:		Line 69:
	</div>		</div>

	[[File:~~W8MD~~-~~Team~~.~~jpg~~\|thumb\|right\|~~350px~~\|[[~~W8MD Weight Loss~~, ~~Sleep~~ and ~~MedSpa~~]] ~~helps patients with semaglutide evaluation, cardiovascular-~~risk ~~focused weight loss, nutrition, sleep apnea screening, and long-term maintenance~~.]]		[[File:Obesity-waist circumference.svg\|thumb\|right\|300px\|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]]
	[[File:~~Woman~~-~~losing-weight~~.~~jpeg~~\|thumb\|~~right~~\|~~350px~~\|~~Cardiovascular~~ risk ~~reduction with semaglutide works best~~ when ~~medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up~~.]]		[[File:Sleep-150.png\|thumb\|left\|220px\|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]]

	==Overview==		==Overview==
Line 135:		Line 135:
	* [[Stroke]]		* [[Stroke]]
	{{div col end}}		{{div col end}}
			[[File:W8MD-Team.jpg\|thumb\|right\|350px\|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]]
			[[File:Woman-losing-weight.jpeg\|thumb\|right\|350px\|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]]
			[[File:Before-and-after-weight-loss.jpeg\|thumb\|right\|350px\|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]]
	This cluster is increasingly described as cardiovascular-kidney-metabolic risk. A patient’s cardiovascular risk is not just a number on a scale. It includes body weight, waist circumference, blood pressure, cholesterol, glucose, sleep apnea, kidney function, family history, smoking status, activity level, medications, and prior cardiovascular events.		This cluster is increasingly described as cardiovascular-kidney-metabolic risk. A patient’s cardiovascular risk is not just a number on a scale. It includes body weight, waist circumference, blood pressure, cholesterol, glucose, sleep apnea, kidney function, family history, smoking status, activity level, medications, and prior cardiovascular events.

Line 237:		Line 239:

	==Semaglutide and stroke risk==		==Semaglutide and stroke risk==
	~~[[File:Before-and-after-weight-loss.jpeg\|thumb\|right\|350px\|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]]~~
	~~[[File:Body mass index chart.svg\|thumb\|right\|300px\|[[Body mass index]] is one tool used to assess obesity-related cardiovascular risk and medication eligibility.]]~~
	~~[[File:Obesity-waist circumference.svg\|thumb\|right\|300px\|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]]~~
	~~[[File:Sleep-150.png\|thumb\|right\|220px\|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]]~~

	[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" />		[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" />

Prab at 18:27, 12 July 2026

2026-07-12T18:27:57Z

← Older revision		Revision as of 18:27, 12 July 2026
Line 5:		Line 5:
	{{Infobox drug		{{Infobox drug
	\| drug_name = Semaglutide and cardiovascular risk		\| drug_name = Semaglutide and cardiovascular risk
	\| image = ~~[[File:Semaglutide structure.svg\|250px]]~~		\| image =
	\| caption = [[Semaglutide]] has evidence for reducing cardiovascular risk in selected patients with [[obesity]], [[overweight]], [[type 2 diabetes]], established [[cardiovascular disease]], and related cardiometabolic conditions.		\| caption = [[Semaglutide]] has evidence for reducing cardiovascular risk in selected patients with [[obesity]], [[overweight]], [[type 2 diabetes]], established [[cardiovascular disease]], and related cardiometabolic conditions.
	\| tradename = [[Wegovy]], [[Ozempic]], [[Rybelsus]]		\| tradename = [[Wegovy]], [[Ozempic]], [[Rybelsus]]
Line 71:		Line 71:
	[[File:W8MD-Team.jpg\|thumb\|right\|350px\|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]]		[[File:W8MD-Team.jpg\|thumb\|right\|350px\|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]]
	[[File:Woman-losing-weight.jpeg\|thumb\|right\|350px\|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]]		[[File:Woman-losing-weight.jpeg\|thumb\|right\|350px\|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]]
	~~[[File:Before-and-after-weight-loss.jpeg\|thumb\|right\|350px\|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]]~~
	~~[[File:Body mass index chart.svg\|thumb\|right\|300px\|[[Body mass index]] is one tool used to assess obesity-related cardiovascular risk and medication eligibility.]]~~
	~~[[File:Obesity-waist circumference.svg\|thumb\|right\|300px\|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]]~~
	~~[[File:Semaglutide structure.svg\|thumb\|right\|300px\|[[Semaglutide]] is the active ingredient in Wegovy, Ozempic, and Rybelsus.]]~~
	~~[[File:Sleep-150.png\|thumb\|right\|220px\|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]]~~

	==Overview==		==Overview==
Line 242:		Line 237:

	==Semaglutide and stroke risk==		==Semaglutide and stroke risk==
			[[File:Before-and-after-weight-loss.jpeg\|thumb\|right\|350px\|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]]
			[[File:Body mass index chart.svg\|thumb\|right\|300px\|[[Body mass index]] is one tool used to assess obesity-related cardiovascular risk and medication eligibility.]]
			[[File:Obesity-waist circumference.svg\|thumb\|right\|300px\|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]]
			[[File:Sleep-150.png\|thumb\|right\|220px\|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]]

	[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" />		[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" />

Prab: Created page with "{{Short description|Semaglutide and cardiovascular risk, Wegovy heart-risk reduction, SELECT trial, Ozempic cardiovascular data, heart failure, kidney outcomes, and W8MD medical weight loss care}} {{DISPLAYTITLE:Semaglutide and cardiovascular risk}} NOTOC {{Infobox drug | drug_name = Semaglutide and cardiovascular risk | image = 250px | caption = Semaglutide has evidence for reducing cardiovascular risk in selected patients wit..."

2026-07-12T18:12:31Z

Created page with "{{Short description|Semaglutide and cardiovascular risk, Wegovy heart-risk reduction, SELECT trial, Ozempic cardiovascular data, heart failure, kidney outcomes, and W8MD medical weight loss care}} {{DISPLAYTITLE:Semaglutide and cardiovascular risk}} __NOTOC__ {{Infobox drug | drug_name = Semaglutide and cardiovascular risk | image = 250px | caption = Semaglutide has evidence for reducing cardiovascular risk in selected patients wit..."

Show changes